[Skip to Content]
[Skip to Content Landing]
July 1995

Oral Calcitriol as a New Therapeutic Agent in Localized and Systemic Scleroderma

Author Affiliations

Department of Dermatology University Hospital 2 Place Saint-Jacques 25030 Besançon Cedex, France


Lille, France

Arch Dermatol. 1995;131(7):850-851. doi:10.1001/archderm.1995.01690190106026

We read the recent case report by Hulshof et al1 in the October 1994 issue of the Archives with interest. The authors described three patients with generalized morphea who were treated with calcitriol (1,25-dihydroxyvitamin D3) in an oral dose of 0.5 to 0.75 μg per day. After 3 to 7 months of treatment, the authors observed a beneficial effect on joint mobility and skin extensibility. Since our first report in 19902 demonstrating the beneficial effect of oral calcitriol in local- ized scleroderma, we conducted a study in 11 patients with systemic sclerosis and seven patients with morphea that also showed the efficacy of oral calcitriol. To date, after a 2- to 36-month treatment period, we confirm our promising data, as published in two recent reports.3-5 Taken together, these results suggest that a high dose of oral calcitriol (mean dose, 1.75 μg/d) may be a useful therapeutic

First Page Preview View Large
First page PDF preview
First page PDF preview